Kathy Glaub

Biography

 Kathy Glaub has served as a director of Codexis since September 2014. Ms. Glaub’s 30-year career in leadership positions with drug development and technology companies brings strong company-building and business strategy experience to our board of directors. In September 2014, Ms. Glaub was appointed as CEO of Afferent Pharmaceuticals, a clinical-stage biotechnology company that is developing treatments for respiratory and urologic disorders and chronic pain, where she has been a member of its board of directors since 2013. Prior to Afferent, Ms. Glaub served as President of and co-led Plexxikon Inc., a biopharmaceutical company that discovers and develops novel, small molecule therapeutics, from 2001 to 2013. Ms. Glaub led the successful buyout of Plexxikon by Daiichi Sankyo in 2011 for nearly $1 billion in cash. While at Plexxikon, Ms. Glaub developed and executed the company’s business and financial strategies, led and negotiated several financings and industry-leading partnership deals that generated $300 million in non-equity funding, and played a key role in building Plexxikon’s product pipeline. Ms. Glaub also negotiated co-promotion rights and established a specialty sales force for the marketing of Zelboraf ®, Plexxikon’s first FDA-approved drug which is marketed with a companion diagnostic. Prior to Plexxikon, Ms. Glaub served as Chief Financial Officer for Cell Genesys, where she led the company’s financial strategy, played a pivotal role in key acquisitions and structured the successful spin out of Abgenix. Previous to Cell Genesys, Ms. Glaub was Treasurer of Genentech and held various financial and treasury roles at Intel Corporation. Ms. Glaub received her BA from the University of California, Berkeley, and her MBA from Northwestern University.

Research Interest

 marketing,business management